Squamous Cell Carcinoma of the Penis: Fourteen-year Experience from a Tertiary Institution
OY Szeto, HC Cheng, WM Ng, KC Ngan
Hong Kong J Radiol 2016;19:111-7
DOI: 10.12809/hkjr1615362
Objective: Penile cancer is a rare disease and more than 95% of the disease is squamous cell carcinoma (SCC). This study aimed to report data of penile SCC from a regional institution in Hong Kong.
Methods: Patients with histologically confirmed SCC of the penis who were referred to our institution between January 2000 and December 2013 were retrospectively identified from our institutional patient database. Clinical, pathological, treatment, and survival data were collected and subsequently analysed.
Results: During the study period, 30 cases of SCC of the penis were identified. The median age of patients was 73 years. Most patients presented with T1-T3 disease and around one-third were node-negative. Radical surgery was performed in 18 patients, of whom two received adjuvant radiotherapy. A further patient received radical brachytherapy and another underwent radical external beam radiotherapy. For those who received radical surgery, 44.4% developed locoregional recurrence. The 5-year disease-free survival and overall survival was 32.8% and 43.8%, respectively. Both patients who received radical radiotherapy developed recurrence. The median overall survival of all the patients was 22 months.
Conclusion: Optimal upfront radical treatment and salvage surgery is vital for survival. Adjuvant treatment may improve survival but further randomised trials are needed to evaluate the optimal treatment strategies for patients with SCC of the penis.
中文摘要
陰莖鱗狀細胞癌：一所提供第三層醫療服務的醫院的14年經驗分享
司徒安頤、鄭海清、吳惠敏、顏繼昌
目的：陰莖癌是一種罕見的疾病，95%以上的病例均屬於鱗狀細胞癌。本研究旨在報告香港一所分區醫院有關陰莖鱗狀細胞癌的數據。
方法：從病人數據庫中找出2000年1月至2013年12月期間到上述醫院並由病理學證實患有陰莖鱗狀細胞癌的病人紀錄。搜集並分析其臨床、病理、治療結果和存活數據的資料。
結果：研究期間陰莖鱗狀細胞癌共有30例。患者年齡中位數73歲。大多數患者屬T1至T3期，三分之一為淋巴結陰性。18例接受根治性手術，其中兩人接受輔助放療。1例接受根治性近距離放療，另1例接受根治性體外放療。接受根治性手術的患者中44.4%有局部復發。五年無病生存率為32.8%，五年總生存率為43.8%。接受根治性放療的兩名患者均有復發。所有患者的總生存中位數為22個月。
結論：對於陰莖鱗狀細胞癌，接受根治性治療和挽救手術至關重要。輔助治療可能可以提高存活率，但還須要進一步的隨機試驗以評估陰莖鱗狀細胞癌患者的最佳治療策略。